ATS 2019 Virtual Final Program

10:00 Dupilumab Reduces Severe Exacerbations and Improves Lung Function Regardless of Baseline Bronchodilator Reversibility in Patients with Uncontrolled Moderate-to-Severe Asthma Enrolled in the LIBERTY ASTHMA QUEST Study/ I. Pavord, M. Castro, K.F. Rabe, N.A. Hanania, A. Papi, J.M. FitzGerald, M.S. Rice, P. Rowe, Y. Lu, N. Amin, H.W. Staudinger, N.M.H. Graham, A. Teper, Oxford, United Kingdom, p.A2624 10:15 A Dose-Ranging Study (TERRANOVA) of Benralizumab for Moderate to Severe Chronic Obstructive Pulmonary Disease/ B.R. Celli, G.J. Criner, D. Singh, M. Bafadhel, V. Backer, A. Ramirez-Venegas, Y.-F. Wei, L. Bjermer, V.H. Shih, S. O’Quinn, N. Makulova, P. Newbold, M. Goldman, U.J. Martin, Boston, MA, p.A2625 10:30 Benralizumab for Chronic Obstructive Pulmonary Disease: Results of the Phase III GALATHEA Trial/ G.J. Criner, B.R. Celli, C.E. Brightling, A. Agusti, A. Papi, F.C. Sciurba, D.D. Sin, C.F. Vogelmeier, M. Kato, V.H. Shih, M. Jison, P. Newbold, M.J. Goldman, U.J. Martin, Philadelphia, PA, p.A2626 10:45 Preservation of Lung Function Observed in a Phase 3 Randomized Controlled Trial of Tocilizumab for the Treatment of Early Systemic Sclerosis/ D. Khanna, C.J.F. Lin, J. Goldin, G. Kim, M. Kuwana, Y. Allanore, A. Batalov, I. Butrimiene, P. Carreira, M. Matucci-Cerinic, O. Distler, D. Martinovic Kaliterna, C.-M. Mihai, M. Mogensen, M. Olesinska, J.E. Pope, G. Riemekasten, T.S. Rodriguez-Reyna, M.J. Santos, J. van Laar, H. Spotswood, J. Siegel, A. Jahreis, D. Furst, C.P. Denton, Ann Arbor, MI, p.A2627 11:00 The Placebo Response on Lung Function in Recent Clinical Trials of Asthma Biologics/ M. Chen, M.C. Peters, B. Yoo, C.T.J. Holweg, C. Lew, San Francisco, CA, p.A2628 CLINICAL MINI SYMPOSIUM B16 ADVANCES IN INTERVENTIONAL PULMONARY 9:15 a.m. - 11:15 a.m. KBHCCD Room C147/C148/C154 (Level 1) Chairing: F. Maldonado, MD, Nashville, TN C. Argento, MD, Chicago, IL Oral Presentations 9:15 Comparing Apples to Apples: Inpatient and 30-Day Mortality Rates Following Transbronchial Cryobiopsy Different Compared to Surgical Lung Biopsy/ J.K. Pannu, L.J. Roller, F. Maldonado, R.J. Lentz, H. Chen, O.B. Rickman, Columbus, OH, p.A2629 9:30 Multicenter Review of Complex Pleural Space Infection Management Reveals High Frequency of Imaging and Subsequent High Cumulative Effective Dose of Radiation/ L.C. Horslen, A.S. Jackson, C.L. Wilshire, C.C. Fuller, J.R. Rayburn, C.R. Gilbert, R.K. Weerasinghe, A.J. Bograd, E. Vallieres, J.A. Gorden, Seattle, WA, p.A2630 9:45 Endobronchial Stenting for Distal Airway Stenosis After Lung Transplant/ D. DiBardino, M. Andronov, A. Haas, A.R. Lanfranco, K.C. Ma, Philadelphia, PA, p.A2631 10:00 Pleuroscopy with Confocal Laser Microscopy: First Diagnostic Elements for Malignancy/ V. Heinen, O. Bonhomme, J.-L. Corhay, B. Duysinx, N. Detrembleur, R. Louis, Liège, Belgium, p.A2632 10:15 Chartis Measurement Is of Additional Diagnostic Value to CT Fissure Completeness Score for the Assessment of Endobronchial Valve Treatment in Severe Emphysema/ K. Klooster, T.D. Koster, C.R. Glösenkamp, D. Theilig, N.W. Suttorp, D.-J. Slebos, R.-H. Hubner, Groningen, Netherlands, p.A2633 10:30 Approximated Perfusion from HRCT May Replace Nuclear Perfusion Imaging for Target Selection in Bronchoscopic Lung Volume Reduction Treatment/ T.D. Koster, E. Hazrati, L.E.G.W. Vanfleteren, R. Posthuma, E.M. van Rikxoort, K. Klooster, J.-P. Charbonnier, D.-J. Slebos, Groningen, Netherlands, p.A2634 10:45 Utility of EBUS Guided Transbronchial Forceps Biopsy with and Without Electrocautery Knife for the Diagnosis of Mediastinal and Hilar Lymphadenopathy in Patients with Suspected Granulomatous and Lymphoproliferative Disorders/ V. Pathak, K. Davidson, R.W. Shepherd, Raleigh, NC, p.A2635 CLINICAL MINI SYMPOSIUM B17 ADVANCES IN ILD THERAPY 9:15 a.m. - 11:15 a.m. KBHCCD Room C155-C156 (Level 1) Chairing: K.A.M. Johannson, MD, MPH, ATSF, Calgary, Canada M.B. Scholand, MD, Salt Lake City, UT Oral Presentations 9:15 Long-Term Safety and Efficacy of Recombinant Human Pentraxin-2 in Patients with Idiopathic Pulmonary Fibrosis/ G. Raghu, B. van den Blink, M.J. Hamblin, A.W. Brown, J.A. Golden, L.A. Ho, M.S. Wijsenbeek, M. Vasakova, A. Pesci, D.E. Antin-Ozerkis, K. Meyer, M. Kreuter, H. Santin-Janin, F. Aubin, G.-J.J. Mulder, R. Gupta, L. Richeldi, Seattle, WA, p.A2636 9:30 Nintedanib Plus Sildenafil Versus Nintedanib Alone in Patients with IPF and Severely Impaired Gas Exchange: Subgroup Analysis by Right Heart Dysfunction/ J. Behr, M. Kolb, J.W. Song, F. Luppi, B. Schinzel, S. Stowasser, M. Quaresma, F.J. Martinez, Munich, Germany, p.A2637 9:45 The Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis Patients with Gefapixant, a P2x3 Receptor Antagonist/ F.J. Martinez, A. Afzal, M.M. Kitt, A. Ford, J.J. Li, Y.-P. Li, J. Smith, New York, NY, p.A2638 10:00 Senolytics in Idiopathic Pulmonary Fibrosis: Preliminary Results from a First-in-Human, Open-Label, Pilot Study/ A.M. Nambiar, J.N. Justice, R. Pascual, S.K. Hashmi, T. Tchkonia, N.K. LeBrasseur, J.L. Kirkland, N. Musi, S.B. Kritchevsky, San Antonio, TX, p.A2639 ATS 2019 • Dallas, TX MONDAY • MAY 20 131 MONDAY MORNING